XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
BUSINESS ACQUISITIONS (Details)
1 Months Ended 3 Months Ended
Jan. 19, 2023
USD ($)
item
shares
May 13, 2022
USD ($)
shares
Jun. 30, 2022
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
BUSINESS ACQUISITIONS            
Contingent consideration $ 1,138,000          
Goodwill       $ 33,160,000   $ 33,160,000
Goodwill       33,160,000   33,160,000
Six months            
BUSINESS ACQUISITIONS            
Shares transferable after lock up period (as a percent)   0.3333%        
GVB Biopharma            
BUSINESS ACQUISITIONS            
Goodwill   $ 44,200   33,161,000    
Debt assumed   4,637,000        
Transaction costs   $ 1,753,000        
Shares issued | shares   32,900,000        
Fair value of shares issued   $ 51,653,000        
Lock up period of shares   6 months        
Increase (decrease) in inventory     $ 978,000      
Goodwill   $ 44,200   33,161,000    
Reduction to goodwill   11,040,000        
Deferred tax liability   627,000   627,000    
Deferred Tax Assets, Valuation Allowance           $ 434,000
Valuation of property plant and equipment   $ 70,000        
GVB Biopharma | Sales, general, and administrative            
BUSINESS ACQUISITIONS            
Acquisition related costs         $ 52,000  
GVB Biopharma | Six months            
BUSINESS ACQUISITIONS            
Lock up period of shares   6 months        
GVB Biopharma | Nine months            
BUSINESS ACQUISITIONS            
Lock up period of shares   9 months        
Shares transferable after lock up period (as a percent)   0.3333%        
GVB Biopharma | One Year            
BUSINESS ACQUISITIONS            
Lock up period of shares   1 year        
GVB Biopharma | Tradename            
BUSINESS ACQUISITIONS            
Royalty rate   1.00%        
GVB Biopharma | Off-market lease            
BUSINESS ACQUISITIONS            
Intangible assets   $ 0        
GVB Biopharma | Customer relationships            
BUSINESS ACQUISITIONS            
Historical customer annual attrition rate   20.00%        
RX Pharmatech Ltd            
BUSINESS ACQUISITIONS            
Number of novel food applications | item 1,276          
Cash consideration $ 200,000          
Equity consideration 503,000          
Target working capital, true up 286,000          
Contingent consideration 1,138,000          
Fair value of contingent consideration 2,127,000          
Intangible assets 1,744,000          
Net asset 93,000          
Excess purchase price 0          
Goodwill $ 0          
Contingent consideration, earn out period 3 years          
Shares issued | shares 465,838          
Cash acquired $ 290,000          
Goodwill 0          
RX Pharmatech Ltd | Sales, general, and administrative            
BUSINESS ACQUISITIONS            
Acquisition related costs       $ 68,000    
RX Pharmatech Ltd | Maximum            
BUSINESS ACQUISITIONS            
Contingent consideration $ 1,550,000